Archive | Oncology

PI3K, Biologic Models,

Phosphoinositide 3-Kinase (PI3K)

3D Print of Phosphoinositide 3-Kinase (PI3K) denoting common mutation sites (E545, H1047) that result in an oncogenic enzyme. This model was created from PDB dataset: 5DXT and visualizes the PI3K inhibitor GDC-0326. Protein Description PI3K are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in […]

Continue Reading 0
PARP1, Zejula, Tesaro, Biologic Models, Protein Model, 3d printed molecule

PARP1 bound by Zejula

This is a visualization of PARP1 bound by Zejula, the first in class drug for women with recurrent ovarian cancer, regardless of BRCA mutation. Zejula is an oral medication taken once daily. Protein Description Poly(ADP-ribose) polymerase 1 (PARP1) is an enzyme that in humans is encoded by the PARP1 gene. It is one of the PARP family of enzymes. PARP1 […]

Continue Reading 0
Pembrolizumab, PD1, Keytruda, Biologic Models

Pembrolizumab bound to PD1

3D print of Pembrolizumab (KEYTRUDA) bound to PD-1. Model available in multiple materials and sizes. “Pembrolizumab (formerly MK-3475and lambrolizumab, trade name Keytruda)[1] is a humanized antibodyused in cancer immunotherapy. It destroys a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1(PD-1) receptor. The drug was initially used in treating metastatic melanoma.” Protein […]

Continue Reading
pembrolizumab_3Dprint

Comparative Analysis Pembrolizumab and PD-1 Receptor Binding Properties

Immunotherapy is the treatment of cancer using antibodies that target points of failure in the life cycle of cancer cells. Many of these therapies involve altering monoclonal antibodies to target specific proteins associated to different types of cancer. Understanding the binding properties of these proteins is of utmost importance. Pembrolizumab, an igG4 Monoclonal Antibody Pembrolizumab […]

Continue Reading
sandstone_egfr_inactivet_gloss1

Inactive EGFR Tyrosine Kinase

This is a 3D print of X-ray crystallography dataset 4HJO, the Crystal Structure of the Inactive EGFR Tyrosine Kinase Domain with Erlotinib. 4TRP Protein Description “Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through […]

Continue Reading